An alternative approach to drug discovery for Alzheimer's disease dementia. (September 2012)

• Record Type: Journal Article
• Authors: Schubert, David; Maher, Pamela
• Is Part Of: Future medicinal chemistry. Volume 4:Number 13(2012)
• Page Start: 1681
• Page End: 1688
• Publication Date: 2012-09
• Subjects: Pharmaceutical chemistry -- Periodicals; 615.19005
• DOI: 10.4155/fmc.12.109
• Languages: English
• ISSNs: 1756-8919

Abstract

There are no drugs that halt the progression of any age-associated neurodegenerative disease. This may be due to the failure of drug developers to recognize that while there are mutations that predispose individuals to disease as they get older, the vast majority of neurodegenerative diseases arise from a confluence of multiple toxic insults. Thus, it is unlikely that the current single-target approach is going to yield useful drugs for these conditions. The identification of multi-target lead compounds is needed and their selection should be based upon a requirement for their efficacy in phenotypic screening assays that reflect the biology of the aging brain. This approach to neurodegenerative disease drug discovery is likely to produce safe and effective drugs.